Shao Haoqing, Wang Liping, Zhang Hualing
School of Traditional Chinese Medicine, Hunan University of Medicine, Huaihua, Hunan, China.
Research and Development Center, Kangpu Pharmaceutical Co., Ltd., Changde, Hunan, China.
Front Cell Infect Microbiol. 2024 Nov 15;14:1502373. doi: 10.3389/fcimb.2024.1502373. eCollection 2024.
Tongxieyaofang (TXYF) was a traditional Chinese medicine (TCM) formula for the treatment of diarrhea with liver stagnation and spleen deficiency syndrome, but the potential targets and mechanisms have not been fully clarified. This study aims to explore the potential mechanisms of TXYF in alleviating diarrhea using network pharmacology and full-length 16S rRNA gene sequencing.
Network pharmacology was applied to identify bioactive compounds and potential targets involved in the role of TXYF in alleviating diarrhea. Meanwhile, a model of diarrhea with liver stagnation and spleen deficiency syndrome was constructed by intragastric administration of extract combined with restraint and tail pinch stress. The effect of TXYF on intestinal mucosal microbiota of diarrhea mice was analyzed by full-length 16S rRNA gene sequencing.
Network pharmacology analysis showed that kaempferol, wogonin, naringenin, and nobiletin were compounds associated with the efficacy of TXYF. TXYF may alleviate diarrhea via multiple BPs and pathways, including TNF signaling pathway, IL-17 signaling pathway, and Toll-like receptor signaling pathway, which are involved in TCM-gut microbiota-host interactions. Then, we found that TXYF administration reshaped the diversity and composition of the intestinal mucosal microbial community of diarrhea mice. , primarily , was enriched by the administration of TXYF. After TXYF administration, the abundance of , particularly , was enriched.
Oral administration of TXYF may alleviate diarrhea through remodeling intestinal mucosal microbiota. Promoting the colonization of beneficial commensal bacteria in the intestinal mucosa through gut microbiota-host interactions may be a potential mechanism of TXYF in the treatment of diarrhea.
痛泻要方(TXYF)是一种用于治疗肝郁脾虚型腹泻的中药方剂,但其潜在靶点和作用机制尚未完全阐明。本研究旨在运用网络药理学和全长16S rRNA基因测序技术探索痛泻要方缓解腹泻的潜在机制。
应用网络药理学识别参与痛泻要方缓解腹泻作用的生物活性化合物和潜在靶点。同时,通过灌胃提取物结合束缚和夹尾应激构建肝郁脾虚型腹泻模型。采用全长16S rRNA基因测序分析痛泻要方对腹泻小鼠肠道黏膜微生物群的影响。
网络药理学分析表明,山奈酚、汉黄芩素、柚皮素和川陈皮素是与痛泻要方疗效相关的化合物。痛泻要方可能通过多种生物学过程(BPs)和信号通路缓解腹泻,包括TNF信号通路、IL-17信号通路和Toll样受体信号通路,这些通路参与了中药-肠道微生物群-宿主相互作用。然后,我们发现给予痛泻要方重塑了腹泻小鼠肠道黏膜微生物群落的多样性和组成。给予痛泻要方后, 主要是 富集。给予痛泻要方后, 的丰度增加,尤其是 富集。
口服痛泻要方可能通过重塑肠道黏膜微生物群来缓解腹泻。通过肠道微生物群-宿主相互作用促进有益共生菌在肠道黏膜的定植可能是痛泻要方治疗腹泻 的潜在机制。